A path toward the clinical translation of nano‐based imaging contrast agents

Abstract

Recently, nanoparticles have evolved ubiquitously in therapeutic applications to treat a range of diseases. Despite their regular use as therapeutic agents in the clinic, we have yet to see much progress in their clinical translation as diagnostic imaging agents. Several clinical and preclinical studies support their use as imaging contrast agents, but their use in the clinical setting has been limited to off‐label imaging procedures (i.e., Feraheme). Since diagnostic imaging has been historically used as an exploratory tool to rule out disease or to screen patients for various cancers, nanoparticle toxicity remains a concern, especially when introducing exogenous contrast agents into a potentially healthy patient population, perhaps rationalizing why several nano‐based therapeutic agents have been clinically translated before nano‐based imaging agents. Another potential hindrance toward their clinical translation could be their market potential, as most therapeutic drugs have higher earning potential than small‐molecule imaging contrast agents. With these considerations in mind, perhaps a clinical path forward for nano‐based imaging contrast agents is to help guide/manage therapy. Several studies have demonstrated the ability of nanoparticles to produce more accurate imaging preoperatively, intraoperatively, and postoperatively. These applications illustrate a more reliable method of cancer detection and treatment that can prevent incomplete tumor resection and incorrect assessment of tumor progression following treatment. The aim of this review is to highlight the research that supports the use of nanoparticles in biomedical imaging applications and offer a new perspective to illustrate how nano‐based imaging agents have the potential to better inform therapeutic decisions. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging

Hybrid core–shell nanoparticles for cell-specific magnetic separation and photothermal heating

“…Whereas most of the literature relating to hybrid magneticplasmonic NPs in biomedical applications has been based of using IONPs covered by a gold shell, 10,11 we chose to explore a reverse NP construction, in which a gold core is surrounded by IONPs. By working with pre-synthesized AuNPs, a better control can be achieved over the LSPR, which is essential for PTH.…”

Multimodal Contrast Agents for Optoacoustic Brain Imaging in Small Animals

“…NIR II probes allow for deeper penetration, improved signal/noise ratio, and more reliable unmixing from strong endogenous hemoglobin background. Many NIR II OA/ fluorescence probes, such as novel NIR II OA probes with DNA-based nanocarriers, PEGylated Au nanoparticles, and SPNs, that are of high chemical stability, low toxicity, and a high signal-to-noise ratio showed great promise for multimodal imaging and photothermal therapy (Jin et al, 2010;Ding et al, 2019;Meng et al, 2019;Sun et al, 2019;Zhang et al, 2019c;Feng et al, 2020;Xu et al, 2020;Joseph et al, 2021;Miyasato et al, 2021). 5) Toward clinical translation: For fluorescence imaging, the U.S.…”

Image-guided cancer surgery: a narrative review on imaging modalities and emerging nanotechnology strategies

“…NPs have an important impact on cancer imaging due to their ability to facilitate the generation of multimodal contrast agents and surface functionalization for precise molecular recognition [ 15 , 16 , 101 , 141 ]. However, two crucial factors should be addressed when analysing the gap between the numerous preclinical studies and the small number of clinical studies.…”